Immunoglobulin G1 [247-Alanine,248-Glutamic Acid,250-Alanine,343-Serine,344-Serine,De-C-Terminal-Lysine], Anti-(Human T Cell Immunoreceptor With Ig And Itim Domains) (Human Monoclonal Bms-986207 ?1-Chain), Disulfide With Human Monoclonal Bms-986207 ?-Chain, Dimer
Endometrial Cancer
Explore 44 assets in Endometrial Cancer →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Compugen Ltd
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04570839CT.gov COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endometrial Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1 [247-Alanine,248-Glutamic Acid,250-Alanine,343-Serine,344-Serine,De-C-Terminal-Lysine], Anti-(Human T Cell Immunoreceptor With Ig And Itim Domains) (Human Monoclonal Bms-986207 ?1-Chain), Disulfide With Human Monoclonal Bms-986207 ?-Chain, Dimer (this asset) | Compugen Ltd | P1/2 | CCC · 48 |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| Lenvatinib | Merck Sharp & Dohme LLC | P3 | BB |
| Pembrolizumab | Eli Lilly and Company | P3 | BB |
| Carboplatin | Eli Lilly and Company | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Eli Lilly and Company | P3 | BB |
| Adriamycin | Yonsei University | P3 | B |
| Technetium-99 | Institut de Cancérologie de Lorraine | P3 | B |
| Indocyanine Green | Institut de Cancérologie de Lorraine | P3 | B |
+42 more in the Endometrial Cancer cohort
Other indications for Immunoglobulin G1 [247-Alanine,248-Glutamic Acid,250-Alanine,343-Serine,344-Serine,De-C-Terminal-Lysine], Anti-(Human T Cell Immunoreceptor With Ig And Itim Domains) (Human Monoclonal Bms-986207 ?1-Chain), Disulfide With Human Monoclonal Bms-986207 ?-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Head And Neck Cancer | — | P1/2 | CC · 46 |
| Non-Small Cell Lung Carcinoma | — | P2 | CC · 46 |
| Ovarian Cancer | — | P1/2 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1 [247-Alanine,248-Glutamic Acid,250-Alanine,343-Serine,344-Serine,De-C-Terminal-Lysine], Anti-(Human T Cell Immunoreceptor With Ig And Itim Domains) (Human Monoclonal Bms-986207 ?1-Chain), Disulfide With Human Monoclonal Bms-986207 ?-Chain, Dimer in Endometrial Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-247-alanine248-glutamic-acid250-alanine343-serine344-serinede-c-terminal-lysine-anti-human-t-cell-immunoreceptor-with-ig-and-itim-domains-human-monoclonal-bms-986207-1-chain-disulfide-with-human-monoclonal-bms-986207-chain-dimer-endometrial-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →